APHTON CORP
10-Q, EX-27, 2000-12-15
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: APHTON CORP, 10-Q, 2000-12-15
Next: CATALYTICA INC, 15-12G, 2000-12-15



<TABLE> <S> <C>




<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial  information  extracted from the Annual
Report on Form 10-K for the year ended January 31, 2000 and the Quarterly Report
on Form 10-Q for the quarter and six months ended July 31, 2000 and is qualified
in its entirety by reference to such financial statements.
</LEGEND>



<MULTIPLIER>                                                       1,000

<S>                                                                <C>
<PERIOD-TYPE>                                                         9-MOS
<FISCAL-YEAR-END>                                               JAN-31-2000
<PERIOD-START>                                                   FEB-1-2000
<PERIOD-END>                                                    OCT-31-2000
<CASH>                                                                5,471
<SECURITIES>                                                         18,570
<RECEIVABLES>                                                     7,950
<ALLOWANCES>                                                          0
<INVENTORY>                                                           0
<CURRENT-ASSETS>                                                 24,619
<PP&E>                                                            1,082
<DEPRECIATION>                                                     (898)
<TOTAL-ASSETS>                                                   33,030
<CURRENT-LIABILITIES>                                            (6,233)
<BONDS>                                                               0
                                                 0
                                                           0
<COMMON>                                                            (16)
<OTHER-SE>                                                      (80,490)
<TOTAL-LIABILITY-AND-EQUITY>                                    (32,753)
<SALES>                                                               0
<TOTAL-REVENUES>                                                  1,162
<CGS>                                                                 0
<TOTAL-COSTS>                                                    12,134
<OTHER-EXPENSES>                                                 10,387
<LOSS-PROVISION>                                                      0
<INTEREST-EXPENSE>                                                    0
<INCOME-PRETAX>                                                 (11,034)
<INCOME-TAX>                                                          0
<INCOME-CONTINUING>                                             (11,034)
<DISCONTINUED>                                                        0
<EXTRAORDINARY>                                                       0
<CHANGES>                                                             0
<NET-INCOME>                                                    (11,034)
<EPS-BASIC>                                                       (0.69)
<EPS-DILUTED>                                                     (0.69)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission